# Did oral semaglutide slow Alzheimer's in Novo Nordisk trials?

Published November 19, 2026 · Updated November 19, 2026 · Data as of November 15, 2026

Novo Nordisk reported on November 24, 2025 that oral semaglutide showed no slowing of Alzheimer's progression compared with placebo in two large trials. [1] The evoke and evoke+ trials enrolled some 3800 people with early Alzheimer's and followed them for 2 years. [1] PepBank holds 934 publications with findings in people for semaglutide, as of November 15, 2026. [2] The FDA approved Rybelsus in 2019 for glycemic control in adults with type 2 diabetes. [3]

## Key points

- Novo Nordisk reported that oral semaglutide showed no slowing of Alzheimer's progression compared with placebo in two large randomized trials. [1]
- After seeing no effect on the Clinical Dementia Rating-Sum of Boxes (CDR-SB), Novo Nordisk canceled a planned 1-year extension of the trials. [1]
- The trials enrolled some 3800 people in the early stages of Alzheimer's and followed them for 2 years. [1]
- PepBank holds 4515 findings in people and 663 registered trials that test semaglutide, as of November 15, 2026. [2]
- The FDA approved Rybelsus in 2019 and the EMA approved Rybelsus in 2020, both for adults with type 2 diabetes. [3, 4]

## What did the evoke trials find?

Novo Nordisk reported that two large randomized, placebo-controlled trials of oral semaglutide in people with Alzheimer's showed no slowing of disease progression compared with placebo. [1] The trials, called evoke and evoke+, enrolled some 3800 people in the early stages of Alzheimer's and followed them for 2 years. [1] [Science reported the result](https://www.science.org/content/article/popular-obesity-drug-fails-hotly-anticipated-alzheimer-s-trials) and named Novo Nordisk, the Danish drugmaker, as the sponsor of the trials. [1]

Curo, a peptide shop with the same owner as PepBank, has a related article. [Retatrutide vs Tirzepatide vs Semaglutide: How the GLP-1 Class Differs (2026)](https://curo.you/insights/retatrutide-vs-tirzepatide-vs-semaglutide-glp-1-class)

## Why did Novo Nordisk cancel the extension?

The Clinical Dementia Rating-Sum of Boxes (CDR-SB) is a widely used measure of cognition and function in Alzheimer's trials. [1] Semaglutide showed no effect on the CDR-SB in the trials. After seeing that, Novo Nordisk canceled the planned 1-year extension. [1]

## What does PepBank hold on semaglutide?

[Semaglutide](https://pepbank.io/p/semaglutide) is one of the [peptides in PepBank](https://pepbank.io/peptides), with 966 studies that gave it as of November 15, 2026. [2] The [semaglutide studies](https://pepbank.io/p/semaglutide/studies) hold 4624 results in PepBank's records. [2]

By [evidence class](https://pepbank.io/methods), PepBank holds 934 publications with findings in people and 20 with findings in animals. [2] PepBank also lists 663 registered trials that test semaglutide. [2]

Semaglutide in PepBank's records, as of November 15, 2026

| Evidence class | Publications | Findings |
| --- | --- | --- |
| In people | 934 publications with findings in people | 4515 findings in people [2] |
| In animals | 20 publications with findings in animals | 59 findings in animals [2] |
| In cells or tissue | 3 publications with findings in cells or tissue | 8 laboratory findings in cells or tissue [2] |
| Predicted by a computer model | 13 publications with findings predicted by a computer model | 42 findings predicted by a computer model [2] |

## Where is oral semaglutide approved?

The FDA approved Rybelsus in 2019 for glycemic control in adults with type 2 diabetes, with diet and exercise. [3] The FDA indication for Rybelsus also includes reducing the risk of major adverse cardiovascular events in high-risk adults with type 2 diabetes. [3] The EMA approved Rybelsus in 2020 for adults with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise. [4]

## What did other trials of oral semaglutide find in people?

One trial in people enrolled adults with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or both. In that trial, oral semaglutide lowered major cardiovascular events versus placebo (hazard ratio 0.86). [5] A trial analysis in adults with type 2 diabetes and ASCVD, CKD, or both examined body weight. In these people, oral semaglutide reduced body weight versus placebo by an estimated 3.26 percentage points at week 156. [6]

## FAQ

### Is oral semaglutide the same as Rybelsus?

PepBank's regulatory record lists Rybelsus as a semaglutide product approved in the US and EU, with the year 2019. [7] The FDA approved Rybelsus in 2019, and the EMA approved Rybelsus in 2020, both for adults with type 2 diabetes. [3, 4] Science reported that the Alzheimer's trials tested a pill form of semaglutide. [1]

### How many people were in the semaglutide Alzheimer's trials?

The evoke and evoke+ trials enrolled some 3800 people in the early stages of Alzheimer's. The trials followed them for 2 years. [1] Science described them as the largest, longest GLP-1 trials ever conducted in a neurodegenerative disease. [1] Novo Nordisk, the Danish drugmaker, sponsored the trials. [1]

### Did Novo Nordisk extend the semaglutide Alzheimer's trials?

Novo Nordisk canceled the planned 1-year extension of the evoke trials. [1] The company decided this after it saw no effect from semaglutide on the Clinical Dementia Rating-Sum of Boxes (CDR-SB). That scale is a widely used measure of cognition and function in Alzheimer's trials. [1]

## Sources

1. Popular obesity drug fails in hotly anticipated Alzheimer’s trials | Science. science.org, 2026-11-18. https://www.science.org/content/article/popular-obesity-drug-fails-hotly-anticipated-alzheimer-s-trials
2. Semaglutide in PepBank. PepBank, 2026-11-15. https://pepbank.io/p/semaglutide
3. Rybelsus (US). DailyMed (U.S. National Library of Medicine), 2026-10-09. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
4. Rybelsus (EU). European Medicines Agency, 2026-10-09. https://www.ema.europa.eu/en/medicines/human/EPAR/rybelsus
5. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. The New England journal of medicine, 2025-03-29. https://pubmed.ncbi.nlm.nih.gov/40162642/ PMID 40162642. Evidence class: human.
6. Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial. JAMA cardiology, 2026-05-01. https://pubmed.ncbi.nlm.nih.gov/41879791/ PMID 41879791. Evidence class: human.
7. Semaglutide: regulatory status in PepBank. PepBank, 2026-10-09. https://pepbank.io/p/semaglutide

How this article is made: PepBank writes its articles from the studies and records in its database. Each claim links to its source. [Read how PepBank collects and classes evidence.](https://pepbank.io/methods)

Canonical: https://pepbank.io/blog/did-oral-semaglutide-slow-alzheimer-s-in-novo-nordisk-trials

This is not medical advice.
